UnitedHealth Group Inc beat Wall Street’s first-quarter earnings estimate by 9.38 percent, but the numbers behind that headline were far less comfortable. The company lost 965,000 Medicare Advantage members in the quarter, and its shares have already bounced 31.24 percent in the past month as investors try to price in what comes next.
Management’s 2026 guidance points to revenue of greater than $439 billion, but that outlook is tied to the planned exit of 1.3 to 1.4 million Medicare Advantage members. That is not a small trim. It is a deliberate retreat from a line of business that has long done much of the heavy lifting for the insurer, even as the company tries to reset its cost base and growth profile.
The weight of the latest numbers shows up in the full-year 2025 results. Operating income collapsed 41.26 percent and net income fell 16.31 percent, a sharp reversal for a company that still carries a forward price-to-earnings ratio near 20. UnitedHealth’s 2.4 percent yield also sits beside a shrinking top line, which makes the valuation look less like a bargain and more like a bet that the worst has already passed.
Part of the problem is still coming from outside the company’s control. CMS rate-flat proposals for 2027 threaten to keep UnitedHealth’s most profitable business in neutral just as it is trying to rebuild momentum, while the Justice Department is pursuing legal actions tied to Medicare program participation. Those pressures land on top of $799 million in residual cyberattack costs that continue to burden the business and a 3 percent decline in Optum Health revenue on contracts that are still structurally unprofitable.
That mix leaves UnitedHealth with a familiar Wall Street problem: the share price can rebound faster than the business can heal. The company has room to tell investors that revenue is still growing and guidance still looks large in absolute terms, but the latest quarter suggests the harder question is not whether the stock can rally again. It is whether UnitedHealth can restore enough margin, membership and regulatory certainty to make that rally last.
